en · de · es · fr · pt
sr9009-notes.peptides6088.com › Info › Mechanism And Preclinical Findings — Practical Notes

Mechanism And Preclinical Findings — Practical Notes

By Editorial Desk · published 2025-10-20 · last reviewed 2025-11-24 · Info

Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

Reference notes

Sedative drugs and sleeping pills, including lorazepam, have been associated with an increased risk of death. Sedation is the side effect people taking lorazepam most frequently report. In a group of around 3,500 people treated for anxiety, the most common side effects complained of from lorazepam were sedation (15.9%), dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Side effects such as sedation and unsteadiness increased with age. Cognitive impairment, behavioral disinhibition and respiratory depression as well as hypotension may also occur.

Spanish descendants in the Masonic exile community with lighter skin tones successfully integrated into Miami, but more trouble was faced by those Afrocuban black and mixed-race members living in the Deep South during the era of Racial segregation in the United States. Where Freemasonry in Cuba had allowed black members since 1868, some of the Lodges in the United States did not allow nonwhite members. After escaping to Florida, Tarajano-Gonzalez issued a declaration that any activities of the Grand Lodge of Cuba would be considered "irregular" and "unlawful" according to their own Masonic tradition, and established the Grand Lodge of Cuba in Exile (Spanish: Gran Logia de Cuba En el Exterior), within the territorial jurisdiction of the Grand Lodge of Florida. They claimed that it was not possible for Freemasonry to exist in a country under a Communist government. They further claimed that the majority of the officers of the Grand Lodge of Cuba had become exiled in the United States. On March 6, 1961, the Grand Lodge in Exile was recognized and granted permission by Edwin Larson, Grand Master of Masons in Florida. On March 15, 1962, the Grand Lodge of Florida proclaimed that they did not recognize any authority of the Freemasons in Cuba, unless those acts were approved by the Grand Master of Masons in Cuba in Exile. In 1963, Grand Master John T. Rose, Jr. of the Grand Lodge of Florida issued an edict which stated their recognition that Grand Master Tarajano-Gonzalez was the only recognized Grand Master of Masons in Cuba.

By the end of the 20th century in North America, few new doctors went directly from medical school into independent, unsupervised medical practice, and more state and provincial governments began requiring one or more years of postgraduate training for medical licensure. Residencies are traditionally hospital-based, and in the middle of the 20th century, residents would often live (or "reside") in hospital-supplied housing. "Call" (night duty in the hospital) was sometimes as frequent as every second or third night for up to three years. Pay was minimal beyond room, board, and laundry services. It was assumed that most young men and women training as physicians had few obligations outside of medical training at that stage of their careers. The first year of practical patient-care-oriented training after medical school has long been termed "internship". Even as late as the middle of the twentieth century, most physicians went into primary care practice after a year of internship. Residencies were separate from internship, often served at different hospitals, and only a minority of physicians did residencies. In the United States, the Libby Zion case, which led to the Libby Zion Law, garnered attention in 1984, shed light on the demanding work hours imposed on medical residents. Responding to this concern, the Association of American Medical Colleges released a position statement in 1988, recommending a cap of 80 work hours per week for residents.

Sources: en.wikipedia.org

Reference notes

== Education and early career == Borchers earned his B.S., M.S. and Ph.D. degrees from the University of Konstanz in Germany. He completed postdoctoral training and worked as a staff scientist at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, in North Carolina. From 2001 to 2006 he directed the UNC–Duke Proteomics Facility and held a faculty position in the Department of Biochemistry and Biophysics at the University of North Carolina at Chapel Hill medical school.

An alternative Theravada interpretation regards the list as describing the arising of mental formations and the resultant notion of "I" and "mine," which are the source of suffering. Understanding the relationships between these phenomena is said to lead to nibbana, complete freedom from the cyclical rebirth cycles of samsara. Traditionally, the reversal of the causal chain is explained as leading to the cessation of mental formations and rebirth. Alex Wayman notes that "according to Buddhist tradition, Gautama discovered this formula during the night of Enlightenment and by working backward from "old age and death" in the reverse of the arising order." Wayman also writes that "in time, the twelve members were depicted on the rim of a wheel representing samsara."

=== Diabetes mellitus === Diabetes mellitus (DM) is an immune-disease characterized by the presence of hyperglycemia. Typically these symptoms are brought about by insulin deficiency. However, there have been many recent articles alluding to a correlation between hsp70, in some cases hsp60, and DM. Another recent article discovered the ratio of ehsp70 and ihsp70 could have an effect on DM, leading to a sufficient biomarker. Serum levels of hsp70 have also been shown to increase over time in patients with diabetes.

This is a bibliography of works by Oscar Wilde (1854–1900), a late-Victorian Irish writer. Chiefly remembered today as a playwright, especially for The Importance of Being Earnest, and as the author of The Picture of Dorian Gray; Wilde's oeuvre includes criticism, poetry, children's fiction, and a large selection of reviews, lectures and journalism. His private correspondence has also been published. Wilde was declared bankrupt to pay legal costs after his conviction for "gross indecency," and his possessions – including manuscripts, letters, books and presentation volumes of all the major literary figures of his day – were sold by auction. This has made bibliographical (and biographical) studies of unpublished work more difficult since they are widely dispersed, some in private ownership. The largest collection of Wilde's letters, manuscripts, and other material relating to his literary circle are housed at the William Andrews Clark Memorial Library. A number of Wilde's letters and manuscripts can also be found at the British Library, as well as public and private collections throughout Britain, the United States and France.

Sources: en.wikipedia.org

Notes from published material

==== United Nations Climate Change Conference ==== On 1 November 2022, the COP27 host Egypt invited then President-elect Lula to visit the summit which raised hopes among climate activists and international organizations officials that Brazil will strengthen its environmental policies. Lula accepted the invitation and, while attending the COP27, promised to fight for a zero deforestation in the Amazon and other biomes. He also promised to have a United Nations Climate Change conference held in the Amazon. On 11 January 2023, Lula announced Brazil was making an official bid for the Brazilian city of Belém to host the COP 30. In May 2023, the UN announced that Belém had been chosen to host the summit, a first for a city in the Amazon region. During the COP28, Lula announced that Brazil would join the OPEC+ initiative, which focuses on integration and discussion between members of the group and other countries. He also announced a plan to recover degraded pasturelands, and to boost overall agriculture productivity through loans by Brazil's BNDES.

=== Spinal muscular atrophy === In 2004, development of an antisense therapy for spinal muscular atrophy began. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen received regulatory approval from FDA and soon after, from other regulatory agencies worldwide.

Smoking is the cause of more than 7 million deaths per year, making it the most common cause of preventable early death. One study found that male and female smokers lose an average of 13 and 15 years of life, respectively, while another measured a loss of life of 7 years. Each cigarette is estimated to shorten life by an average of 11 minutes, though this may vary slightly depending on the contents and brand. More recently, it has been reported to be 20 minutes. At least half of all lifelong smokers die early as a result of smoking. Smokers are three times more likely to die before the age of 70 than non-smokers. In the United States, cigarette smoking and exposure to tobacco smoke account for roughly one in five, or at least 443,000 premature deaths annually. To put this into context, ABC's Peter Jennings (who would later die at 67 from lung cancer caused by life-long smoking) famously reported that in the US alone, smoking tobacco kills the equivalent of three jumbo jets full of people crashing every day, with no survivors. On a worldwide basis, this equates to a single jumbo jet every hour. A 2015 study found that about 17% of mortality due to cigarette smoking in the United States is due to diseases outside of those commonly linked with smoking. Official estimates may therefore be significantly underestimating the number of deaths currently being attributed to smoking. It is estimated that there are between 1 and 1.4 deaths per million cigarettes smoked. Cigarette factories are the most deadly factories in the history of the world.

Pyruvate is plentiful in muscle due to extensive glycolysis. Amino groups in skeletal muscles are transferred to a product of glycolysis, pyruvate, forming alanine. This transamination reaction is catalyzed by alanine aminotransferase. Alanine is then transported to the liver, where it is converted back into pyruvate (used for gluconeogenesis) by transferring its amino group to α-ketoglutarate, forming glutamate. Simultaneously, glucose is being transported from the liver (where it's more abundant due to gluconeogenesis) to the muscle, where it is consumed. This is the glucose-alanine cycle.

Cyclodextrins are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by α-1,4 glycosidic bonds. Cyclodextrins are produced from starch by enzymatic conversion. They are used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering. Cyclodextrins are composed of 5 or more α-D-glucopyranoside units linked 1 → 4, as in amylose (a fragment of starch). Typical cyclodextrins contain a number of glucose monomers ranging from six to eight units in a ring, creating a cone shape:

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network